Navigation Links
Sanofi Withdraws Anti-obesity Drug in US

French pharmaceutical group Sanofi-Aventis said Friday it had withdrawn an application for regulatory approval for its anti-obesity drug Acomplia in the United States.

A panel of experts from the US Food and Drug Administration concluded earlier this month that the dieting treatment, referred to as rimonabant by the company, was unsafe and should not be sold in the United States.

"Sanofi-Aventis will work towards submitting the rimonabant file to the FDA at a future date," the company said, adding that it will "undertake the necessary discussions with the FDA to determine the required modifications to its file."

The FDA's expert panel concluded that suicidal thoughts appeared to be a side-effect of taking Acomplia, which has been authorised in the European Union.

The FDA was expected to heed the opinion of the panel of experts and block the sale of the drug.

Sanofi had previously forecast annual sales of 3.0 billion euros (4.0 billion dollars) for the drug.

In a separate development, European regulators said they were reviewing data on the psychiatric effects of Acomplia.

The European Medicines Agency (EMEA) said it expected to announce its conclusions at the end of a July 16-19 meeting.

The agency "is currently reviewing the available data on psychiatric events (in particular suicidal ideation and depression-related events)," it said.

Acomplia has been authorised in 37 countries and is currently sold in 18.


'"/>




Page: 1

Related medicine news :

1. FDA Gives Green Signal To Sanofi-Aventis SAs Cancer Drug Taxotere
2. Sanofi-Aventis sets the ball rolling for trials of H7N1 bird flu vaccine
3. Diabetes II May Be Controlled By Sanofis New Obesity Pill
4. Sanofi-Aventis Allows Thais To Make Plavix
5. Bayer Voluntarily Withdraws BAYCOL - A Drug Associated With 50 Deaths
6. Hospital Withdraws McDonalds Reward Scheme
7. Beef Firm in US Withdraws Its Products from Markets After E. Coli Outbreak.
8. Anti-obesity drugs for FDA approval
9. Canada Confronts Obesity Head-on, Anti-obesity Campaign on Fast Track
10. Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... ... January 17, 2017 , ... ... the National Association of Music Merchants (NAMM) winter trade show, Booth #2876, at ... Etymotic’s ER•4® has long been the gold standard for high-definition, in-ear earphones. This ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... Palm Desert, is opening a new office in San Clemente, California this month. ... (dTMS) in Southern California, successfully treating individuals struggling with major depression. Depression impacts ...
(Date:1/17/2017)... ... 2017 , ... Medic-CE , a Career Step company ... released four new continuing education courses as part of its Code3 CME Virtual ... classroom and meet the requirements of the National Continued Competency Program (NCCP), the ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from New ... eye care practitioners on the latest breakthroughs in the prevention, diagnosis and treatment ... Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... with Sigfox in the U.S.A. to offer Internet of Things (IoT) ... offerings on large-scale environmental sensor deployments such as monitoring solutions used to detect ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Interpace Diagnostics Group, Inc., (NASDAQ: IDXG ), a ... pathology services for evaluating risks of cancer, announced today ... 2017 from the NASDAQ Listing Qualifications notifying the Company ... the NASDAQ Stock Market to maintain a minimum closing ... letter noted that for the last 10 days from ...
(Date:1/17/2017)... 17, 2017 Tempus, a technology company ... University Hospitals Seidman Cancer Center have joined together ... data, advanced molecular analysis and clinical decision support ... healthcare providers. As part of ... transcriptomic sequencing and analysis for ovarian and triple ...
(Date:1/17/2017)... , Jan. 17, 2017  CSSi, the global ... the clinical research industry, will exhibit at the 8 ... Executives (SCOPE 2017), taking place from Tuesday, January 24 ... Miami in Miami, FL. ... proprietary technology platform, SmartStudy™ EMR, which provides a revolutionary ...
Breaking Medicine Technology: